natgillin/translations-raw huggingface dataset:
Mouth ulceration, stomatitis ulcerative, stomatitis, aphthous stomatitis, dyspepsia, cheilosis, glossitis, gastroesophageal reflux, rectal disorder, gastrointestinal disorder, constipation, loose stools, toothache, tooth disorder, stomach discomfort, oral pain
razjede v ustih, ulcerozni stomatitis, stomatitis, aftičen stomatitis, dispepsija, heiloza, glositis, gastroezofagealni refluks, bolezen danke, bolezen prebavil, zaprtje, mehko blato, zobobol, zobna bolezen, neugodje v trebuhu, bolečine v ustih
Seminal transfer of ribavirin has been studied.
Proučevali so prehajanje ribavirina v semensko tekočino.
Uncommonly reported side effects (may affect up to 1 in 100 people):
Občasno prijavljeni neželeni učinki (pojavijo se lahko pri največ 1 od 100 bolnikov):
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Immediate packaging (blister foil)
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU
Pain in extremity, back pain, muscle contracture
artritis, bolečine v hrbtu, mišični krči, bolečine v udih
Females of childbearing potential must use an effective contraceptive during treatment and for four months after treatment has been concluded; routine monthly pregnancy tests must be performed during this time (see section 4.4).
V tem času morajo vsak mesec rutinsko opravljati teste nosečnosti (glejte poglavje 4.4).
Each tablet contains 200 mg of ribavirin
Ena tableta vsebuje 200 mg ribavirina.
1,200 mg/day) d + interferon alfa-2b (3 MIU TIW)
ribavirin 1.200 mg/dan) d + interferon alfa-2b (3 mio i.e., TNT)
The following side effects have been reported with the combination of ribavirin and an alpha interferon product in adults:
in zdravil, ki vsebujejo interferon alfa, pri odraslih so poročali o naslednjih neželenih učinkih:
Very commonly reported side effects (may affect more than 1 in 10 people):
Zelo pogosto prijavljeni neželeni učinki (pojavijo se lahko pri več kot 1 od 10 bolnikov):
Pruritus, photosensitivity reaction, maculopapular rash, hyperhidrosis, eczema, acne, skin disorder, nail disorder, skin discolouration, dry skin, erythema, bruise
Pogosti pruritus, preobčutljivostna reakcija za svetlobo, makulopapulozni izpuščaj, ekcem, hiperhidroza, akne, kožne bolezni, bolezni nohtov, obarvanje kože, suha koža, eritem, podplutbe
If you are not sure, talk to your doctor or pharmacist before taking Ribavirin Teva Pharma B.V. if you: - are allergic to ribavirin or any of the other ingredients of this medicine (listed in section 6).
Če ste negotovi, se posvetujte z zdravnikom ali farmacevtom, preden začnete jemati zdravilo Ribavirin Teva Pharma B.V.
Ribavirin Teva Pharma B.V. 400 mg film-coated tablets ribavirin
400 mg filmsko obložene tablete ribavirin
Each tablet contains 400 mg of ribavirin
Ena tableta vsebuje 400 mg ribavirina.
Dyspnoea, tachypnea, epistaxis, coughing, nasal congestion, nasal irritation, rhinorrhoea, sneezing, pharyngolaryngeal pain
dispneja, tahipneja, epistaksa, kašelj, zamašen nos, draženje nosne sluznice, rinoreja, kihanje, faringolaringealne bolečine
Laboratory values for HCV/HIV co-infected patients
Laboratorijske vrednosti pri bolnikih, sočasno okuženih s HCV in HIV:
• Ribavirin (1,000/1,200 mg/day) + peginterferon alfa-2b (1.5 micrograms/kg/week for one month followed by 0.5 microgram/kg/week for 11 months) (n = 514).
 ribavirin (1.000/1.200 mg/dan) + peginterferon alfa-2b (1,5 mikrogramov/kg na teden en mesec,
Fatigue, rigors, pyrexia, influenza like illness, asthenia, irritability
utrujenost, mrzlica, zvišana telesna temperatura, gripi podobna bolezen, astenija, razdražljivost
Bone pain, muscle weakness
bolečine v kosteh, mišična šibkost
A decrease in haemoglobin levels to < 10 g/dL was observed in up to 14 % of adult patients and 7 % of children and adolescents treated with ribavirin in combination with peginterferon alfa-2b or interferon alfa-2b in clinical trials.
V kliničnih preskušanjih so pri do 14 % odraslih bolnikov in 7 % otrok in mladostnikov, zdravljenih z ribavirinom v kombinaciji s peginterferonom alfa-2b ali interferonom alfa-2b, opažali znižanje vrednosti hemoglobina na < 10 g/dl.
- anti-Human Immunodeficiency Virus (HIV) medicines - [nucleoside reverse transcriptase inhibitor (NRTI), and/or combined anti-retroviral therapy (cART)]: Taking this medicine in combination with an alpha interferon and an anti-HIV medicine may increase the risk of lactic acidosis, liver failure, and blood abnormalities development (reduction in number of red blood cells which carry oxygen, certain white blood cells that fight infection, and blood clotting cells called platelets).
jemljete tega zdravilo v kombinaciji z interferonom alfa in zdravilom proti virusu HIV lahko poveča tveganje za pojav laktacidoze, odpovedi jeter in razvoja krvnih nepravilnosti (zmanjšanje števila rdečih krvničk, ki prenašajo kisik po telesu, določenih belih krvničk, ki služijo za boj proti okužbam, in celic za strjevanje krvi, ki jim pravimo trombociti).
Fatigue, rigors, pyrexia, influenza-like illness, asthenia, malaise, irritability
utrujenost, mrzlica, zvišana telesna temperatura, gripi podobna bolezen, astenija, splošno slabo počutje, razdražljivost
How to use Ribavirin Teva Pharma B.V.
Kako jemati zdravilo Ribavirin Teva Pharma B.V.
- are pregnant or planning to become pregnant (see section “Pregnancy and breast-feeding”).
- če ste alergični na ribavirin ali katero koli sestavino tega zdravila (navedeno v poglavju 6), - če ste noseči ali načrtujete nosečnost (glejte poglavje “Nosečnost in dojenje ”), - če dojite,
Ribavirin Teva Pharma B.V. 200 mg film-coated tablets ribavirin
200 mg filmsko obložene tablete ribavirin
Pancytopenia: Ribavirin Teva Pharma B.V. can cause a decrease in your platelet and red and white blood cell count when used in combination with peginterferon.
lahko v kombinaciji s peginterferonom povzroči zmanjšanje števila krvnih ploščic (trombocitov) in rdečih ter belih krvnih celic.
Visual disturbance, blurred vision, conjunctivitis, eye irritation, eye pain, abnormal vision, lacrimal gland disorder, dry eye
motnje vida, zamegljen vid, konjunktivitis, draženje očesa, bolečine v očeh, motnje vida, bolezni solzne žleze, suho oko
If needed, 2nd dose reduction of Ribavirin Teva Pharma B.V. is by an additional 200 mg/day.
Če je potrebno, lahko opravite tudi drugo zmanjšanje odmerka zdravila Ribavirin Teva Pharma B.V.
Haematological abnormalities in HCV/HIV co-infected patients:
Hematološke motnje pri bolnikih, sočasno okuženih s HCV in HIV:
Usual daily Ribavirin Teva Pharma B.V. dose
Običajni dnevni odmerek zdravila Ribavirin Teva Pharma B.V.
Haemolysis: Ribavirin Teva Pharma B.V. can cause a break down in red blood cells causing anaemia which may impair your heart function or worsen symptoms of heart disease.
lahko povzroči razgradnjo rdečih krvnih celic in posledično anemijo, kar lahko poslabša delovanje srca ali poslabša simptome bolezni srca.
abnormal behaviour, emotional disorder, fear, nightmare, bleeding of the mucous membrane that lines the inner surface of the eyelids, blurred vision, drowsiness, intolerance to light, itchy eyes, facial pain, inflamed gums, chest discomfort, difficult breathing, lung infection, nasal discomfort, pneumonia,wheezing, low blood pressure, enlarged liver, painful menstruation, itchy anal area (pinworms or ascarids), blistering rash (shingles), decreased sensitivity to touch, muscle twitching, pain in skin, paleness, peeling of skin, redness, swelling.
neprenašanje svetlobe, srbenje oči, obrazne bolečine, vnetje dlesni, - tiščanje v prsih, težko dihanje, pljučne okužbe, neprijeten občutek v nosu, pljučnica, piskanje v pljučih, - nizek krvni tlak, - povečana jetra, - boleče menstruacije, - srbenje v predelu zadnjika (podančice ali askaride), izpuščaj z mehurji (herpes zoster ali pasovec),
For complete information be sure to read the “How to use” section of the Package Leaflet for the other medicines used in combination with Ribavirin Teva Pharma B.V..
“Kako uporabljati zdravilo” v navodilih za uporabo za druga zdravila, uporabljena v kombinaciji z zdravilom Ribavirin Teva Pharma B.V..
severe rashes which may be associated with blisters in the mouth, nose, eyes and other mucosal membranes (erythema multiforme, Stevens Johnson syndrome), toxic epidermal necrolysis (blistering and peeling of the top layer of skin).
(multiformni eritem, Stevens-Johnsonov sindrom), toksično epidermalno nekrolizo (mehurjenje in luščenje povrhnje plasti kože).
EU/1/09/527/001 (14 tablets) EU/1/09/527/002 (28 tablets) EU/1/09/527/003 (42 tablets) EU/1/09/527/004 (56 tablets) EU/1/09/527/005 (84 tablets) EU/1/09/527/006 (112 tablets) EU/1/09/527/007 (140 tablets) EU/1/09/527/008 (168 tablets)
EU/1/09/527/001 (14 tablet) EU/1/09/527/002 (28 tablet) EU/1/09/527/003 (42 tablet) EU/1/09/527/004 (56 tablet) EU/1/09/527/005 (84 tablet) EU/1/09/527/006 (112 tablet) EU/1/09/527/007 (140 tablet) EU/1/09/527/008 (168 tablet)
Drug hypersensitivity
preobčutljivost za zdravila
The active substance is Ribavirin.
- Zdravilna učinkovina je ribavirin.
EU/1/09/527/009 (14 tablets) EU/1/09/527/010 (28 tablets) EU/1/09/527/011 (42 tablets) EU/1/09/527/012 (56 tablets) EU/1/09/527/013 (84 tablets) EU/1/09/527/014 (112 tablets) EU/1/09/527/015 (140 tablets) EU/1/09/527/016 (168 tablets)
EU/1/09/527/009 (14 tablet) EU/1/09/527/010 (28 tablet) EU/1/09/527/011 (42 tablet) EU/1/09/527/012 (56 tablet) EU/1/09/527/013 (84 tablet) EU/1/09/527/014 (112 tablet) EU/1/09/527/015 (140 tablet) EU/1/09/527/016 (168 tablet)
Ribavirin Teva Pharma B.V. dose based on body weight when used in combination with interferon alfa-2b or peginterferon alfa-2b in children above 3 years of age and adolescents
na podlagi telesne mase pri otrocih, starejših od 3 let, in mladostnikih, če je zdravilo uporabljeno v kombinaciji z interferonom alfa-2b ali peginterferonom alfa-2b
Ribavirin Teva Pharma B.V. must be used in combination therapy as described in section 4.1.
je treba uporabljati v kombinaciji z drugimi zdravili, kot je opisano v poglavju 4.1.
SVR after treatment of chronic HCV with non-pegylated interferon alfa-2b with ribavirin results in long-term clearance of the virus providing resolution of the hepatic infection and clinical 'cure' from chronic HCV.
SVR po zdravljenju kronične okužbe s HCV z nepegiliranim interferonom alfa-2b in zdravilom Ribavirin Teva Pharma B.V.
EU/1/09/527/009 - 14 tablets EU/1/09/527/010 - 28 tablets EU/1/09/527/011 - 42 tablets EU/1/09/527/012 - 56 tablets EU/1/09/527/013 - 84 tablets EU/1/09/527/014 - 112 tablets EU/1/09/527/015 - 140 tablets EU/1/09/527/016 - 168 tablets
EU/1/09/527/009 - 14 tablet EU/1/09/527/010 - 28 tablet EU/1/09/527/011 - 42 tablet EU/1/09/527/012 - 56 tablet EU/1/09/527/013 - 84 tablet EU/1/09/527/014 - 112 tablet EU/1/09/527/015 - 140 tablet EU/1/09/527/016 - 168 tablet
In combination with peginterferon alfa-2b
Kombinirana terapija s peginterferonom alfa-2b
EU/1/09/527/001 - 14 tablets EU/1/09/527/002 - 28 tablets EU/1/09/527/003 - 42 tablets EU/1/09/527/004 - 56 tablets EU/1/09/527/005 - 84 tablets EU/1/09/527/006 - 112 tablets EU/1/09/527/007 - 140 tablets EU/1/09/527/008 - 168 tablets
EU/1/09/527/001 - 14 tablet EU/1/09/527/002 - 28 tablet EU/1/09/527/003 - 42 tablet EU/1/09/527/004 - 56 tablet EU/1/09/527/005 - 84 tablet EU/1/09/527/006 - 112 tablet EU/1/09/527/007 - 140 tablet EU/1/09/527/008 - 168 tablet
Conjunctivitis, eye pain, abnormal vision, lacrimal gland disorder
konjunktivitis, bolečine v očeh, motnje vida, bolezni solzne žleze
Table 1 Ribavirin Teva Pharma B.V. dose based on body weight when used in combination with interferon alfa-2b in paediatric patients
na podlagi telesne mase, ko se pri pediatrični populaciji uporablja v kombinaciji z interferonom alfa-2b telesna masa bolnika (kg)
The concomitant use of ribavirin with zidovudine is not recommended due to an increased risk of anaemia (see section 4.4).Consideration should be given to replacing zidovudine in a combination anti-retroviral treatment (ART) regimen if this is already established.
Pri zdravljenju z uveljavljeno kombinirano protivirusno shemo (ART) je treba premisliti o zamenjavi zidovudina.
How to store Ribavirin Teva Pharma B.V.
Kaj je zdravilo Ribavirin Teva Pharma B.V.
Female: amenorrhea, menorrhagia, menstrual disorder, dysmenorrhea, breast pain, ovarian disorder, vaginal disorder.
Pogosti ženske: amenoreja, menoragija, menstrualne motnje, dismenoreja, bolečine v dojkah, bolezni jajčnikov, bolezni nožnice; moški: impotenca, prostatitis, motnje erekcije, spolne motnje (neopredeljene)*
Both the Metavir score and Ishak grade decreased among subjects treated with ribavirin in combination with peginterferon alfa-2b.
V dveh preskušanjih so raziskovali ribavirin v kombinaciji z interferonom alfa-2b, v dveh pa ribavirin v kombinaciji s peginterferonom alfa-2b.
Haemoglobin levels dropped below 10 g/dL in up to 14 % of adult patients and 7 % of children and adolescents treated with ribavirin in combination with either peginterferon alfa-2b or interferon alfa-2b.
Pri do 14 % odraslih bolnikov in 7 % otrok in mladostnikov, zdravljenih z ribavirinom v kombinaciji bodisi s peginterferonom alfa-2b ali z interferonom alfa-2b, se je vrednost hemoglobina znižala pod 10 g/dl.
Ribavirin concentration in seminal fluid is approximately two-fold higher compared to serum.
Pri uporabi ribavirina se lahko zaradi hemolize zviša koncentracija sečne kisline.
Posology
Bolnice
EFFECTIVE USE OF THE MEDICINAL PRODUCT
Imetnik dovoljenja za promet z zdravilom
This medicine must not be used without interferon alfa-2b, i.e.
To zdravilo ustavi razmnoževanje številnih vrst virusov, vključno z virusom hepatitisa C. Tega zdravila ne smete uporabljati brez interferona alfa-2b, torej zdravila Ribavirin Teva Pharma B.V.
In combination with interferon alfa-2b
Kombinirana terapija z interferonom alfa-2b
Tablet coating
Bolezni prebavil
Ribavirin 15 mg/kg/day interferon alfa-2b 3 MIU/m2 3 times a week
Preglednica 9 Trajen virološki odziv pri predhodno nezdravljenih otrocih in mladostnikih ribavirin 15 mg/kg/dan interferon alfa-2b 3 mio i.e./m2 3-krat na teden
In clinical trial C/I98-580, 1,530 naïve patients were treated for one year with one of the following combination regimens:
V kliničnem preskušanju C/I98-580 je 1.530 predhodno nezdravljenih bolnikov leto dni prejemalo enega od naslednjih kombiniranih režimov zdravljenja:  ribavirin (800 mg/dan) + peginterferon alfa-2b (1,5 mikrogramov/kg na teden) (n = 511).
Tabulated list of adverse reactions for adults
Glejte odmerek za odrasle
Tél/Tel: +32 3 820 73 73
Teva Pharma Belgium S.A. Belgien/ Belgique Tél/Tel: +32 3 820 73 73
Commonly reported side effects (may affect up to 1 in 10 people):
Pogosto prijavljeni neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov):
Hepatic function
Srčnožilni učinki
The safety of ribavirin is evaluated from data from four clinical trials in patients with no previous exposure to interferon (interferon-naïve patients): two trials studied ribavirin in combination with interferon alfa-2b, two trials studied ribavirin in combination with peginterferon alfa-2b.
Varnost uporabe ribavirina so ovrednotili na podlagi izsledkov štirih kliničnih preskušanj pri bolnikih, ki še niso bili izpostavljeni interferonu (predhodno nezdravljeni bolniki).
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
The recommended dose and duration of Ribavirin Teva Pharma B.V. depends on patient's weight and on the medicinal product that is used in combination.
Priporočeni odmerek in trajanje zdravljenja z zdravilom Ribavirin Teva Pharma B.V.
feeling depressed or irritable, feeling sick to stomach, feeling unwell, mood swings, tired feeling, trouble falling asleep or staying asleep, virus infection, weakness, diarrhoea, dizziness, fever, flu-like symptoms, headache, loss of or increase in appetite, loss of weight, decrease in the rate of growth (height and weight), pain on right side of ribs, pharyngitis (sore throat), shaking chills, stomach pain, vomiting, dry skin, hair loss, irritation, itching, muscle pain, muscle aches, pain in joints and muscles, rash.
- zmanjšanje števila rdečih krvničk (kar lahko povzroči utrujenost, kratko sapo in omotico); zmanjšanje števila nevtrofilcev (zaradi katerega boste lahko bolj občutljivi za različne okužbe), - zmanjšanje delovanja žleze ščitnice (zaradi katerega se boste lahko počutili utrujeno in depresivno ter se bo povečala vaša nagnjenost k prehladom in drugim simptomom), - občutek depresivnosti ali razdražljivosti, občutek slabosti v želodcu, slabo počutje, nihanje razpoloženja, občutek utrujenosti, težave z uspavanjem ali zbujanje, virusna okužba, občutek šibkosti, - driska, omotica, zvišana telesna temperatura, gripi podobni simptomi, glavobol, izguba teka ali povečanje teka, izguba telesne mase, zmanjšana hitrost rasti (tako kar zadeva rast v višino kot pridobivanje telesne mase), bolečina na desni strani reber, faringitis (vnetje žrela), mrzlica s tresenjem, želodčne bolečine, bruhanje, - suha koža, izpadanje las, draženje, srbenje, mišične bolečine, bolečine v sklepih in mišicah, izpuščaj.
These reactions can sometimes be serious.
Včasih so lahko te reakcije resne;
Tell your doctor straight away if:
Takoj povejte svojemu zdravniku, če:
It may be acceptable to extend the duration of stimulation in any one cycle to up to 5 weeks.
Sprejemljivo je podaljšanje trajanja stimulacije v katerem koli ciklusu do 5 tednov.
Note: Please check that the medicine is not frozen.
Opomba: prepričajte se, da zdravilo ni zamrznjeno.
• Treatment is continued until your eggs have developed to a desired point.
• Zdravljenje se nadaljuje, dokler se jajčeca ne razvijejo do želene točke.
Your doctor will decide how much medicine you will use and how often.
Vaš zdravnik bo določil, koliko zdravila boste uporabili in kako pogosto.
This usually takes about 10 days but can take any time between 5 and 20 days.
To običajno traja približno 10 dni, vendar je razpon lahko kadar koli med 5 in 20 dni.
Following subcutaneous administration, the absolute bioavailability is about 70%.
Po subkutani uporabi je absolutna biološka razpoložljivost 70 %.
However, it should be taken into account that there are variations between LH measurements performed in different laboratories.
Vendar je treba upoštevati, da so razlike med rezultati meritev LH, ki so izvedene v različnih laboratorijih.
If you are a woman, this medicine increases your risk of developing OHSS.
Če ste ženska, to zdravilo povečuje vaše tveganje za razvoj OHSS.
Date of latest renewal:
Datum zadnjega podaljšanja:
• Bemfola is usually given every day.
• Zdravilo Bemfola se običajno daje vsak dan.
It is advised to adhere to the recommended starting doses indicated below.
Svetujemo, da se upoštevajo spodaj navedeni priporočeni začetni odmerki.
The doses described below are stated in International Units (IU) and millilitres (mL).
Odmerki, opisani spodaj, so navedeni v mednarodnih enotah (i.e.) in mililitrih (ml).
Differences between the 2 groups were statistically significant (p< 0.05) for all criteria listed.
Razlike med obema skupinama so bile po vseh navedenih merilih statistično značilne (p < 0,05).
It most often occurs after hormonal treatment has been discontinued and reaches its maximum at about seven to ten days following treatment.
Najpogosteje se pojavi po prekinitvi hormonskega zdravljenja in doseže vrhunec približno sedem do deset dni po zdravljenju.
A multiple pregnancy may lead to medical complications for you and your babies.
Večplodne nosečnosti lahko vodijo v zdravstvene zaplete pri vas in vaših otrocih.
OHSS may progress rapidly (within 24 hours) or over several days to become a serious medical event.
OHSS se lahko hitro (v 24 urah) ali v nekaj dneh razvije v resen zdravstven zaplet.
urinary FSH (n = 116)
FSH v urinu (n = 116)
• You will use these two medicines three times a week for at least 4 months.
• Ti dve zdravili boste uporabili trikrat na teden vsaj štiri mesece.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 27/03/2014
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve odobritve: 27/03/2014
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Z namenom, da bi izboljšali sledljivost bioloških zdravil, morata biti ime in številka serije uporabljenega zdravila jasno zabeležena.
Tell your doctor before you start treatment, if you or any member of your family have porphyria (an inability to break down porphyrins that may be passed on from parents to children).
Pred začetkom zdravljenja povejte zdravniku, če imate vi ali kdo v družini porfirijo (nezmožnost razgradnje porfirinov, ki se lahko prenaša s staršev na otroke).
Overall experience with IVF indicates that in general the treatment success rate remains stable during the first four attempts and gradually declines thereafter.
Celokupne izkušnje z IVF kažejo, da je na splošno uspeh zdravljenja v prvih štirih poskusih stalen, nato pa se postopno zmanjšuje.
1103 Budapest Hungary
1103 Budapest Madžarska
It should be noted however that pregnancy itself as well as OHSS also carry an increased risk of thromboembolic events.
Vendar moramo upoštevati, da nosečnost sama in tudi OHSS prinašata povečano tveganje za trombembolične dogodke.
There is evidence to suggest that hCG plays a key role in triggering OHSS and that the syndrome may be more severe and more protracted if pregnancy occurs.
Obstajajo dokazi, ki kažejo na to, da ima hCG odločilno vlogo pri sprožitvi OHSS in da je sindrom lahko hujši in daljši, če pride do nosečnosti.
You will need it after the injection.
Po injiciranju ga boste potrebovali.
Take the pen out of the fridge 5 to 10 minutes before using it.
Injekcijski peresnik vzemite iz hladilnika od 5 do 10 minut pred uporabo.
Clinical efficacy and safety in men
Klinična učinkovitost in varnost pri moških
No teratogenic effect has been observed in animal studies (see section 5.3).
V poskusih na živali niso opazili nobenega teratogenega učinka (glejte poglavje 5.3).
To minimise skin irritation, select a different injection site each day.
Da zmanjšate draženje kože, izberite vsak dan drugo mesto injiciranja.
Since these patients are amenorrhoeic and have low endogenous estrogen secretion, treatment can commence at any time.
Ker so te bolnice amenoreične in imajo nizko sekrecijo endogenega estrogena, se lahko zdravljenje začne kadar koli.
• If you have not responded to treatment after 4 months, your doctor may suggest that you continue using these two medicines for at least 18 months.
• Če se po štirih mesecih ne odzovete na zdravljenje, vam bo zdravnik morda predlagal, da nadaljujete uporabo teh dveh zdravil vsaj 18 mesecev.
In adult men
Pri odraslih moških
Find a clean area • A good place is a clean table or surface.
• Primerna površina je čista miza ali površina.
In these women, the benefits of gonadotropin administration need to be weighed against the risks.
Pri teh ženskah je treba pretehtati koristi uporabe gonadotropinov glede na tveganje.
The majority of multiple conceptions are twins.
V večini večplodnih zanositev gre za dvojčke.
Alternatively intrauterine insemination (IUI) may be performed.
Alternativno se lahko izvede intrauterina inseminacija (IUI).
Therefore patients should be followed for at least two weeks after hCG administration.
Zato je treba bolnice spremljati najmanj dva tedna po dajanju hCG.
Children and adolescents Bemfola is not indicated for use in children and adolescents under 18 years of age.
Zdravilo Bemfola ni indicirano pri otrocih in mladostnikih, mlajših od 18 let.
This is thought to be due to differences in parental characteristics (e.g. maternal age, sperm characteristics) and multiple pregnancies.
To se pripisuje razlikam lastnosti staršev (npr. materina starost, lastnosti sperme) in večplodnim nosečnostim.
In men, FSH is needed for the production of sperm.
Moški potrebujejo FSH za tvorbo sperme.
Do not use Bemfola if any of the above applies to you.
Ne uporabljajte zdravila Bemfola, če kar koli od zgoraj naštetega velja za vas.
If you are a man, having too much FSH in your blood can be a sign of damaged testicles.
Če ste moški in imate previsoko raven FSH v krvi, je morda to znak za poškodbo testisov.